GlassScriptPhysician profile
Laura J Martin
NPI 1790883767
$2,028.06
in general payments reported to CMS, 2019-2025
16 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $11.06 · 2021: $128 · 2022: $99.56 · 2023: $45.18 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,544.08 | 2019 | |
| Medtronic, INC. | $150.09 | 2021-2025 | Signia, Synchromedii |
| Merck Sharp & Dohme LLC | $60.89 | 2021-2023 | Keytruda, Lynparza |
| Stryker Corporation | $34.54 | 2022 | |
| Paratek Pharmaceuticals, INC. | $30.15 | 2019 | |
| Acacia Pharma INC | $29.59 | 2021-2022 | |
| Biotronik Nro, INC. | $26.58 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $24.76 | 2025 | |
| Collegium Pharmaceutical, INC. | $21.54 | 2025 | Xtampza |
| Daiichi Sankyo INC. | $19.61 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.92 | 2019 | |
| Seagen INC. | $18.65 | 2019 | |
| Amgen INC. | $14.35 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.